louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05434455: Effect of RIPC on the Prevention of POD in Patients Undergoing Cardiac Surgery
Official title: Effects of Remote Ischemic Preconditioning(RIPC) on the Prevention of Postoperative Delirium in Patients Undergoing Cardiac Surgery: A Pilot Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Postoperative Delirium
Cardiac Surgery
Lead sponsor: Shanghai Zhongshan Hospital
Sponsor class: OTHER
First posted: 2022-06-28
Enrollment: 216
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Postoperative delirium (POD) is one of the most frequent neurological complications in elderly patients and is closely associated with longer ICU stay and hospitalization, deterioration of long-term neurocognitive function, and increased mortality. The incidence of POD is significantly higher in elderly patients undergoing cardiac surgery than in other populations. Therefore, the prevention of POD is an important clinical problem to be solved urgently. In this study, we intend to observe the effect of RIPC on the prevention and treatment of POD in patients undergoing cardiac surgery through a prospective randomized controlled trial.


Eligibility criteria: Inclusion Criteria:

* patients undergoing elective cardiac surgery;
* age ≥ 18 yr;
* any sex;
* American Society of Anesthesiologists (ASA) class ≥II class;
* New York Heart Association (NYHA) ≥II class.

Exclusion Criteria:

* emergency surgery;
* a history of cardiovascular surgery;
* peripheral vascular disease affecting the upper limbs;
* acute myocardial infarction (MI) up to 14 days before surgery;
* a history of severe injuries and operations within 3 months before cardiac surgery;
* a history of cancer and chronic autoimmune diseases.

Primary outcomes:
measure: Incidence of postoperative delirium
timeFrame: 7 days postoperatively or before discharge, whichever came first
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00526955: Duration and Force Variations in Applied Kinesiology Manual Muscle Testing
Official title: Duration and Force Variations in Applied Kinesiology Manual Muscle Testing
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Keywords: Manual muscle testing
Lead sponsor: Logan College of Chiropractic
Sponsor class: OTHER
First posted: 2007-09-10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE

Brief summary: To investigate the effect of duration of Applied Kinesiology manual muscle testing on "strong" versus "weak" result of the test.


Eligibility criteria: Inclusion Criteria:

* Over 18 years of age,
* willing to participate

Exclusion Criteria:

* Major injury or conditions which would prevent muscle testing of the shoulder.

Primary outcomes:
measure: Force over time during a manual muscle test and a maximal voluntary isometric contraction
timeFrame: 1 to 6 seconds
Secondary outcomes:
measure: Facilitated (strong) or inhibited (weak) rating of muscle
timeFrame: 1 to 6 seconds
Other outcomes:
Locations:
city: Chesterfield
country: United States
facility: Logan College of Chiropractic
state: Missouri
Study officials:
affiliation: Logan College of Chiropractic
name: Katharine M Conable, D.C.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04407455: Determining Chewing Performance Level in Children
Official title: Inter-rater Reliability in Determining Chewing Performance Level in Children
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chewing Problem
Lead sponsor: Hacettepe University
Sponsor class: OTHER
First posted: 2020-05-29
Enrollment: 97
Sex: ALL
Minimum age (years): 2
Maximum age (years): 12
Standard ages: CHILD
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Typical developing children and children with cerebral palsy (CP) who will be referred to pediatric dentistry above the age of 2 years.

Brief summary: The study will investigate to verify whether pediatric dentists could determine chewing performance level by using Karaduman Chewing Performance Scale in children.

Detailed description: The KCPS was developed by physical therapists who had expertise in pediatric swallowing disorders. This scale could be used as a practical tool to define chewing disorders as a common language for professionals due to its quick and easy to use features. However, its reliability in other professions has not been verified. The study will investigate to verify whether pediatric dentists could determine chewing performance level by using Karaduman Chewing Performance Scale in children.

Eligibility criteria: Inclusion Criteria:

* Typical developing children
* Children with cerebral palsy (CP)
* Above the age of 2 years

Exclusion Criteria:

* Children who were under the age of 2 years
* Who used any medicine and/or oral appliances that may affect chewing performance
* Who had a previous evaluation of chewing function and received any chewing training

Primary outcomes:
measure: Karaduman Chewing Performance Scale
timeFrame: 2 months
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Hacetttepe University
Study officials:
affiliation: Hacettepe University
name: SELEN SEREL ARSLAN
role: PRINCIPAL_INVESTIGATOR
References:
citation: Serel Arslan S, Ozsin Ozler C, Demir N, Ozturk S, Uzamis Tekcicek M, Karaduman AA. Pediatric dentists can determine chewing performance level in children. Clin Oral Investig. 2021 Aug;25(8):5043-5048. doi: 10.1007/s00784-021-03815-w. Epub 2021 Feb 2.
Clinical trial NCT04594655: MPI Predicts Outcome of CRC Elderly Patients (MPI=MULTIDIMENSIONAL PROGNOSTIC INDEX; CRC=COLORECTAL CANCER)
Official title: Multidimensional Prognostic Index (MPI) Score Has the Major Impact on Outcome Prediction in Elderly Surgical Patients With Colorectal Cancer: the Fragis Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Colorectal Cancer
Fragility
Elderly
Lead sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Sponsor class: OTHER
First posted: 2020-10-20
Enrollment: 104
Sex: ALL
Minimum age (years): 75
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: CRC patients aged ≥75 years

Brief summary: Patients aged ≥75 year scheduled for CRC surgery were studied (104 cases) and variables associated with major postoperative complications / mortality were evaluated. The importance of this report is that MPI-score resulted strongly associated with major complications and it was a primary component of an individual prediction model.

Detailed description: Patients aged ≥75 year scheduled for CRC surgery were studied (104 cases) and variables associated with major postoperative complications / mortality were evaluated. The MPI (multidimensional prognostic index)-score resulted strongly associated with major complications. also, it was a primary component of an individual prediction model (LASSO model).

Eligibility criteria: Inclusion Criteria:

All CRC patients aged ≥75 years, who were scheduled for elective surgery and able to express their consent to treatment, were considered.

Exclusion Criteria: emergency surgery; patients aged \<75 years; patients unable to sign informed consent.

Primary outcomes:
measure: MPI and major morbidity
timeFrame: 30 days
Secondary outcomes:
measure: Prediction of complication
timeFrame: 90 days
Other outcomes:
Locations:
city: Brescia
country: Italy
facility: ASST Spedali Civili
state: Lombardia
Study officials:
affiliation: ASST Spedali Civili di Brescia
name: Uberto Fumagalli, MD
role: STUDY_CHAIR
References:
Clinical trial NCT06083155: The NetherLands Registry of Invasive Coronary Vasomotor Function Testing (NL-CFT)
Official title: The NetherLands Registry of Invasive Coronary Vasomotor Function Testing (NL-CFT)
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Coronary Vasospasm
Coronary Microvascular Dysfunction
Non-Obstructive Coronary Atherosclerosis
Lead sponsor: Radboud University Medical Center
Sponsor class: OTHER
Collaborators: name: UMC Utrecht
name: Catharina Ziekenhuis Eindhoven
name: Maasstad Hospital
name: VieCuri Medical Centre
name: Frisius Medisch Centrum
name: Haaglanden Medical Centre
name: Rijnstate Hospital
name: Medisch Spectrum Twente
name: Onze Lieve Vrouwe Gasthuis
name: Tergooi Hospital
name: Amphia Hospital
name: Elisabeth-TweeSteden Ziekenhuis
name: Noordwest Ziekenhuisgroep
name: Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
First posted: 2023-10-13
Enrollment: 2000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients referred for clinically indicated CFT are eligible

Brief summary: The goal of this registry is to collect data on patients referred for clinically indicated coronary vasomotor function test (CFT) and answer different questions on prevalence, safety and outcomes. The registry is observational. Patients receive yearly online questionnaires on their anginal complaints for 5 years after their CFT.


Eligibility criteria: Inclusion Criteria:

* Referred for clinically indicated CFT

Exclusion Criteria:

* Not willing to provide informed consent

Primary outcomes:
measure: Prevalence of coronary vasomotor dysfunction
timeFrame: Baseline
Secondary outcomes:
measure: Angina burden
timeFrame: Baseline and every year up to 5 years after baseline
measure: Experienced quality of life
timeFrame: Baseline and every year up to 5 years after baseline
Other outcomes:
Locations:
city: Nijmegen
country: Netherlands
facility: RadboudUMC
state: Gelderland
city: Amsterdam
country: Netherlands
facility: Amsterdam UMC
city: Amsterdam
country: Netherlands
facility: Onze Lieve Vrouwe Gasthuis (OLVG)
city: Arnhem
country: Netherlands
facility: Rijnstate Hospital
city: Breda
country: Netherlands
facility: Amphia Hospital
city: Den Haag
country: Netherlands
facility: Haaglanden Medisch Centrum
city: Eindhoven
country: Netherlands
facility: Catharina Ziekenhuis
city: Enschede
country: Netherlands
facility: Medisch Spectrum Twente
city: Hilversum
country: Netherlands
facility: Tergooi Hospital
city: Leeuwarden
country: Netherlands
facility: Medisch Centrum Leeuwarden
city: Maastricht
country: Netherlands
facility: Maastricht UMC
city: Rotterdam
country: Netherlands
facility: Maasstad Ziekenhuis
city: Tilburg
country: Netherlands
facility: Elisabeth-TweeSteden Hospital
city: Utrecht
country: Netherlands
facility: UMC Utrecht
city: Venlo
country: Netherlands
facility: VieCuri Medisch Centrum
Study officials:
affiliation: Radboud University Medical Center
name: Peter Damman
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00412555: A Study of Tamiflu (Oseltamivir) for Seasonal Prophylaxis of Influenza in Children.
Official title: An Open-label Multi-center Trial of Oseltamivir for the Seasonal Prophylaxis of Influenza in Children.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Influenza
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
First posted: 2006-12-18
Enrollment: 52
Sex: ALL
Minimum age (years): 1
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This study will evaluate the safety of Tamiflu, when used for the prevention of influenza in children during the flu season. Children who would benefit from influenza prophylaxis when influenza is circulating in the community will receive treatment with Tamiflu syrup (or capsules) 30mg-75mg once daily (dependent on body weight) for 6 weeks. Safety data and influenza symptoms will be recorded throughout the study. The anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.


Eligibility criteria: Inclusion Criteria:

* males or females, 1-12 years of age;
* candidate for seasonal prophylaxis;
* negative rapid diagnostic test for influenza at baseline.

Exclusion Criteria:

* symptoms suggestive of influenza-like illness;
* positive rapid diagnostic test for influenza;
* antiviral treatment for influenza in 2 weeks prior to randomization.

Primary outcomes:
measure: AEs, laboratory parameters, vital signs.
timeFrame: Throughout study
measure: Percentage of patients with laboratory confirmed clinical influenza
timeFrame: Throughout study
Secondary outcomes:
measure: Percentage of subjects with asymptomatic influenza; percentage with an influenza-like illness.
timeFrame: Throughout study
Other outcomes:
Locations:
city: West Palm Beach
country: United States
state: Florida
city: Pittsburgh
country: United States
state: Pennsylvania
city: Jackson
country: United States
state: Tennessee
city: El Paso
country: United States
state: Texas
city: Coquitlam
country: Canada
state: British Columbia
city: Aalborg
country: Denmark
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_DIRECTOR
References:
citation: Reisinger K, Shu D, Cupelli L, Marcadis I, Dutkowski R. Safety and tolerability of a 6-week course of oseltamivir prophylaxis for seasonal influenza in children. Influenza Other Respir Viruses. 2013 Jan;7(1):11-3. doi: 10.1111/j.1750-2659.2012.00367.x. Epub 2012 Apr 23.
Clinical trial NCT03818555: Sebacia Postmarket Study of Real-World Use
Official title: A Prospective, Multicenter, Postmarket Study of Sebacia Microparticles Treatment in Patients Using Topical Acne Products for Mild to Moderate Inflammatory Acne Vulgaris
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Acne Vulgaris
Lead sponsor: Sebacia, Inc.
Sponsor class: INDUSTRY
First posted: 2019-01-28
Enrollment: 125
Sex: ALL
Minimum age (years): 12
Maximum age (years): 45
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Postmarket study of Sebacia Microparticles treatment during adoption into clinical use for patients with mild to moderate inflammatory acne vulgaris.


Eligibility criteria: Inclusion Criteria:

* Mild to moderate facial inflammatory acne vulgaris (IGA 2 or 3)
* Between 10 and 50 papules/pustules
* Fitzpatrick skin phototype I, II or III
* Able to provide informed consent and comply with study schedule and other requirements

Exclusion Criteria:

* Moderately severe or severe acne vulgaris (IGA 4 or 5)
* Nodulocystic acne, significant scarring or excoriation
* Requires oral retinoid, antibiotic or corticosteroid for acne
* New or fluctuating hormone or hormone-regulating therapy
* Photosensitivity or allergy to gold
* Medical or mental health condition that would pose a risk to patient or impair treatment and evaluation

Primary outcomes:
measure: Inflammatory Lesion Count
timeFrame: Months 2, 3, 6, 9 and 12
Secondary outcomes:
measure: Investigator's Global Assessment
timeFrame: Months 2, 3, 6, 9 and 12
measure: Physician's Overall Assessment of Improvement
timeFrame: Months 2, 3, 6, 9 and 12
Other outcomes:
Locations:
city: Miami
country: United States
facility: Miami Dermatology & Laser Institute
state: Florida
city: Boston
country: United States
facility: Dermatology Institute of Boston
state: Massachusetts
city: Murfreesboro
country: United States
facility: International Clinical Research
state: Tennessee
city: Austin
country: United States
facility: Austin Institute for Clinical Research - Central
state: Texas
city: Pflugerville
country: United States
facility: Austin Institute for Clinical Research - Pflugerville
state: Texas
city: Spokane
country: United States
facility: Premier Clinical Research
state: Washington
Study officials:
affiliation: Sebacia, Inc.
name: VP, Clinical & Regulatory Affairs
role: STUDY_DIRECTOR
References:
Clinical trial NCT04471155: Comparison of Holmium Laser Enucleation Prostatectomy and Open Transvesical Prostatectomy in Large Prostate
Official title: Comparison of Holmium Laser Enucleation Prostatectomy and Open Transvesical Prostatectomy in Large Prostate More Than 80 Grams in Egyptian Men
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Benign Prostatic Hyperplasia
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2020-07-15
Enrollment: 110
Sex: MALE
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: randomized controlled trial
Primary purpose: TREATMENT

Brief summary: comparison of holmium laser enucleation prostatectomy and open prostatectomy regarding safety and efficacy in men with prostate larger than 80 grams


Eligibility criteria: Inclusion Criteria:

* American Urological Association Symptom Score of eight or higher,
* Maximum urinary flow rate of 10ml/s or less,
* Post void residual urine volume of 50 ml or more,
* And a total prostate volume of 80 ml or more in transrectal ultrasound (TRUS).

Exclusion Criteria:

* A previous prostate or urethral surgery
* And non-BPH related voiding disorders
* Prostate cancer patients

Primary outcomes:
measure: efficacy by measuring maximum urinary flow rate in millilitre per second
timeFrame: 1 year
measure: efficacy in american urological association symptom score
timeFrame: 1 year
measure: efficacy of evacuation by measuring post-voiding residual urine volume in millilitre
timeFrame: 1 year
Secondary outcomes:
measure: safety by doing blood picture to asses hemoglobin drop
timeFrame: immediate post-operative
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Mohamed Alnoomani
state: القاهرة
Study officials:
References:
Clinical trial NCT04468555: Hallux Valgus Manual Therapy Based on Global Postural Reeducation.
Official title: Effects of Global Postural Reeducation on Hallux Valgus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hallux Valgus
Hallux Deformity
Foot Deformities
Lead sponsor: University of Jaén
Sponsor class: OTHER
First posted: 2020-07-13
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: A single-blind randomized controlled trial.
Primary purpose: TREATMENT

Brief summary: Manual approach of Hallux Valgus with global postural reeducation.

Detailed description: Hallux Abducto Valgus is a frequent pathology with a prevalence of 30% in women and 13% in men. The tendency is to increase with age.

Usually, the elected treatment is surgery, as the conservative orthopedic methods are used at the early stages of the pathology. Global Postural Re-Education is a manual therapy treatment method through which we can treat lots of pathologies. Some investigations demonstrate Postural Re-Education is effective for the treatment of temporomandibular disorders, urinary incontinence, and spine disorders, but there is no scientific evidence that defends the improvement of the symptoms and correction of the angle of the Hallux Abducto Valgus using Postural Re-Education.

Eligibility criteria: Inclusion Criteria:

* hallux abducto valgus with an angle between 15 - 39º
* pain on the medial or plantar face of the forefoot
* Physical independence to take part in the study.

Exclusion Criteria:

* Being under hallux abducto valgus treatment.
* Lower limb surgery.
* Fracture or disfunction on the lower limb other than hallux valgus which may affect the studied variables.

Primary outcomes:
measure: Postural control
timeFrame: From baseline to 3 weeks and 8 weeks.
Secondary outcomes:
measure: Dynamic balance
timeFrame: From baseline to 3 weeks and 8 weeks.
measure: Ankle range of motion
timeFrame: From baseline to 3 weeks and 8 weeks.
measure: Self-reported instability
timeFrame: From baseline to 3 weeks and 8 weeks.
measure: Assessment of the grade of hallux valgus
timeFrame: From baseline to 3 weeks and 8 weeks.
measure: Foot posture
timeFrame: From baseline to 3 weeks and 8 weeks.
measure: Passive and active dorsiflexion range of motion of the 1st metatarsophalangeal joint
timeFrame: From baseline to 3 weeks and 8 weeks.
measure: Gait parameters
timeFrame: From baseline to 3 weeks and 8 weeks.
measure: Functional status
timeFrame: From baseline to 3 weeks and 8 weeks.
Other outcomes:
Locations:
city: Jaen
country: Spain
facility: University of Jaen
Study officials:
affiliation: University of Jaén
name: David Cruz-Diaz, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06748755: A Comparative Analysis of Ultrasound's Accuracy in Diagnosing HC Using Histopathology as Gold Standard
Official title: A Comparative Analysis of Ultrasound's Accuracy in Diagnosing Hepatocellular Carcinoma Using Histopathology as Gold Standard
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Hepatocellular Carcinoma
Lead sponsor: Superior University
Sponsor class: OTHER
First posted: 2024-12-27
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: aim is to check the accuracy of Ultrasound's in Diagnosing Hepatocellular Carcinoma Using Histopathology as Gold Standard

Brief summary: The study aims to evaluate the accuracy of ultrasound in diagnosing hepatocellular carcinoma (HCC), using histopathology as the gold standard. It addresses HCC's high global incidence and the utility of ultrasound as a non-invasive, cost-effective screening tool. Despite ultrasound's accessibility, its diagnostic limitations necessitate further investigation to improve clinical outcomes.


Eligibility criteria: Inclusion Criteria:

* Clinically suspected liver cancer patients undergoing ultrasound examination.
* Patients undergoing histopathological examination (liver biopsy or resection) for definitive diagnosis.

Exclusion Criteria:

- Patients with history of liver cancer treatment or inadequate data."

Primary outcomes:
measure: ultrasound
timeFrame: 12 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Gujrānwāla
country: Pakistan
facility: Medcare International Hospital
state: Punjab
Study officials:
References: